130 related articles for article (PubMed ID: 10910485)
1. Desflurane as a marker of limb-to-systemic leak during hyperthermic isolated limb perfusion.
Stanley G; Sundarakumaran R; Crowley R; Kavanah M
Anesthesiology; 2000 Aug; 93(2):574-6. PubMed ID: 10910485
[No Abstract] [Full Text] [Related]
2. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb.
Skene AI; Bulman AS; Williams TR; Thomas JM; Westbury G
Br J Surg; 1990 Jul; 77(7):765-7. PubMed ID: 2383752
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
6. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
[TBL] [Abstract][Full Text] [Related]
7. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
8. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
[TBL] [Abstract][Full Text] [Related]
9. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
[TBL] [Abstract][Full Text] [Related]
10. [Technique and results of hyperthermic perfusion of the extremity in melanoma patients].
Omlor G; Bahmer F; Meessen S; Zang D; Feifel G; Zaun H
Langenbecks Arch Chir; 1993; 378(1):21-5. PubMed ID: 8437498
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic isolation limb perfusion for malignant melanoma: a review.
Coit DG
Cancer Invest; 1992; 10(4):277-84. PubMed ID: 1628227
[No Abstract] [Full Text] [Related]
12. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
13. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
14. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
[TBL] [Abstract][Full Text] [Related]
15. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
Cheng TY; Grubbs E; Abdul-Wahab O; Leu SY; Hung CF; Petros W; Aloia T; Fedrau R; Pruitt S; Colvin M; Friedman H; Tyler D
Am J Surg; 2003 Nov; 186(5):460-7. PubMed ID: 14599607
[TBL] [Abstract][Full Text] [Related]
16. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
17. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
Thompson JF; Lai DT; Ingvar C; Kam PC
Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
[TBL] [Abstract][Full Text] [Related]
18. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR; Hart GA
Am J Surg; 1994 Jun; 167(6):618-20. PubMed ID: 8209941
[TBL] [Abstract][Full Text] [Related]
19. Regional hyperthermic perfusion for malignant melanoma.
Hafström LO; Ehrson H; Hugander A; Jönsson PE; Westling H
Prog Clin Biol Res; 1982; 107():793-8. PubMed ID: 7167529
[No Abstract] [Full Text] [Related]
20. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
Santillan AA; Zager JS
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
